Everolimus-Eluting Platinum Chromium Coronary Stent System
Abluminal bioabsorbable polymer (BP) application
Emphasizes suppression of neointimal growth at the arterial wall while promoting healing inside the vessel.
Thin, rounded struts
Stents with thinner strut designs have been shown to heal faster than thicker strut stents.1
Fast-absorbing bioabsorbable polymer
Polymer is gone when it is no longer needed, shortly after the drug is completely eluted.2
Optimal drug release
Market-leading Everolimusdrug is completely eluted with optimal kinetics at 3 months.
Lower Inflammation Rates3
In a preclinical model, SYNERGY™ BP Stent demonstrated:
- Significantly reduced Early Inflammation versus Bare Metal Stents (BMS)
- Significantly reduced Late Inflammation versus Permanent Polymer (PP) Stents
Not All Bioabsorbable Polymer Stents are Created Equal
Optimal Healing Shown Through Strut Coverage and Angioscopy
Angioscopy demonstrates differentiated and improved healing with SYNERGY™ BP Stent.9
Angioscopy is also able to detect the quality of neointimal coverage that we are not able to see with OCT.
† Images courtesy of Takafumi Ueno, MD; Division of Cardiovascular Medicine, Kurume University School of Medicine, Kureme, Japan.
‡ Image captured at 13-month follow-up
. § Image captured at 12-month follow-up
SYNERGY™ Clinical Overview
Discover the clinical evidence on the SYNERGY™ BP Stent, including multiple short DAPT studies.
Learn about the continued advancement in deliverability that SYNERGY™ offers.